Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

2017335 citationsJournal Articlebronze Open Access

Authors

Thomas A. Hope · American College of Radiology

Emily K. Bergsland · American Society of Clinical Oncology

Murat Fani Bozkurt · European Association of Nuclear Medicine

Michael M. Graham · Society of Nuclear Medicine and Molecular Imaging

Anthony P. Heaney · Endocrine Society

Ken Herrmann · European Association of Nuclear Medicine

James R. Howe

Abstract

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used

Topics & Keywords

Neuroendocrine Tumor Research Advances Neuroblastoma Research and Treatments Lung Cancer Research Studies

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Journal of Nuclear Medicine

Volume 59, Issue 1, pp. 66-74

DOI: 10.2967/jnumed.117.202275

Field-Weighted Citation Impact: 15.61